2020-11-06T12:02:01-06:00 2019-12-31 043077056 MOODY FAMIGLIETTI & ANDRONICO LLP 1 HIGHWOOD DRIVE TEWKSBURY MA 01876 990 2019-01-01 463250612 EVIDENCE FOR HEALTHCARE IMPROVEMENT EVID 6175284013 TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 SARAH EMOND CHIEF OPERATING OFFICER 6175284013 2020-11-05 MATTHEW KALIL CPA MBA P01517069 9785575300 2020-11-05 64.27.39.203 2020-11-05 08:48:12 ES P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 4141E4A5C25AD619B9DECADFBF31C872A80AFA19 2019 2021-01-29 14:40:06Z INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW STEVEN D PEARSON MD TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 10872122 0 X ICER-REVIEW.ORG X 2013 CA SEE SCHEDULE O 8 8 37 0 0 0 1124458 10471183 972936 389717 3428 6969 3219 4253 2104041 10872122 0 0 0 0 3696729 4166102 0 0 277608 2604255 2543909 6300984 6710011 -4196943 4162111 9910517 14188477 1081054 741403 8829463 13447074 X FAIR PRICING, FAIR PATIENT ACCESS, AND FUTURE INNOVATION. 0 0 1535166 NEW DRUG ASSESSMENT PROGRAM: ICER'S PROGRAM TO EVALUATE NEW DRUGS AT OR NEAR THE TIME OF FDA APPROVAL PROVIDES AN INDEPENDENT ANALYSIS OF THE COMPARATIVE EFFECTIVENESS OF NEW DRUGS, ALONG WITH AN ASSOCIATED "HEALTH-BENEFIT PRICE BENCHMARK," WITH THE OBJECTIVE OF HELPING DECISION-MAKERS UNDERSTAND AND APPLY EVIDENCE TO IMPROVE VALUE THROUGHOUT THE HEALTH CARE SYSTEM. THE REPORTS OF THE NEW DRUG ASSESSMENT PROGRAM ARE VETTED THROUGH A PUBLIC PROCESS AND ITERATIVE ENGAGEMENT WITH PATIENTS, CAREGIVERS, AND CLINICAL EXPERTS. 1239921 THE NEW ENGLAND COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (NEW ENGLAND CEPAC), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE NEW ENGLAND CEPAC CONVENES MULTIPLE TIMES EACH YEAR AT PUBLIC MEETINGS TO APPRAISE OBJECTIVE EVIDENCE REPORTS, TAKE PUBLIC VOTES ON THE CLINICAL AND ECONOMIC VALUE OF HEALTH CARE INTERVENTIONS, AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE. 1148427 THE MIDWEST COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (MIDWEST CEPAC), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE MIDWEST CEPAC CONVENES MULTIPLE TIMES EACH YEAR AT PUBLIC MEETINGS TO APPRAISEOBJECTIVE EVIDENCE REPORTS, TAKE PUBLIC VOTES ON THE CLINICAL AND ECONOMIC VALUE OF HEALTH CARE INTERVENTIONS, AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE. 1029619 THE CALIFORNIA TECHNOLOGY ASSESSMENT FORUM (CTAF), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE CALIFORNIA TECHNOLOGY ASSESSMENT FORUM CONVENES MULTIPLE TIMES EACH YEAR AT PUBLIC MEETINGS TO APPRAISE OBJECTIVE EVIDENCE REPORTS, TAKE PUBLIC VOTES ON THE CLINICAL AND ECONOMIC VALUE OF HEALTH CARE INTERVENTIONS, AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE. 438866 355750 MEMBERSHIP: RENAMED AS THE POLICY LEADERSHIP FORUM (PLF), THE ICER MEMBERSHIP PROGRAM LAUNCHED IN 2015 TO GIVE A SELECT NUMBER OF LEADING HEALTH CARE ORGANIZATIONS A UNIQUE OPPORTUNITY TO SHAPE THE FUTURE OF EVIDENCE AND COVERAGE POLICY IN THE U.S. THE TENSION BETWEEN INNOVATION AND HEALTH CARE COSTS CONTINUES TO FOCUS CRITICAL ATTENTION ON HOW EVIDENCE WILL BE DEVELOPED BY MANUFACTURERS AND HOW IT WILL BE INTERPRETED BY PAYERS IN MAKING COVERAGE DECISIONS. BENEFITING FROM ICER'S EXPERIENCE AS A LEADER IN HEALTH TECHNOLOGY ASSESSMENT, AND ITS UNIQUE ABILITY TO SERVE AS AN ENGAGED, OBJECTIVE CONVENER AND MODERATOR, THE POLICY LEADERSHIP FORUM BRINGS TOGETHER A SMALL, INFLUENTIAL GROUP OF EVIDENCE LEADERS FROM PUBLIC AND PRIVATE PAYER ORGANIZATIONS, HEALTH TECHNOLOGY ASSESSMENT GROUPS, AND LIFE SCIENCE COMPANIES TO ADDRESS KEY CONTROVERSIES IN EVIDENCE METHODS AND POLICY. WORKING TOGETHER IN A BALANCED, NON-ADVERSARIAL ENVIRONMENT, PLF MEMBERS GAIN THE SKILLS AND INSIGHTS IN EVIDENCE POLICY NECESSARY TO STRENGTHEN THEIR COMPETITIVE POSITION IN THE MARKETPLACE. 171926 33967 OTHER ACTIVITIES INCLUDING SPEAKING FEES AND SMALL POLICY PROJECTS. 1640411 389717 5563925 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 69 0 1 37 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA MA X THE ORGANIZATION 6175284013 TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 MARK SKINNER DIRECTOR 1.00 X 0 0 0 LEWIS SANDY DIRECTOR 1.00 X 0 0 0 ANYA RADER WALLACK DIRECTOR 1.00 X 0 0 0 CARMELLA BOCCHINO RN MBA DIRECTOR 1.00 X 0 0 0 WENDY EVERETT SCD DIRECTOR 1.00 X 0 0 0 RON POLLACK JD DIRECTOR 1.00 X 0 0 0 TANISHA CARINO DIRECTOR (UNTIL 10/8/19) 1.00 X 0 0 0 FRANCES VISCO DIRECTOR (UNTIL 10/30/19) 1.00 X 0 0 0 ELLEN ANDREWS DIRECTOR 1.00 X 0 0 0 MURRAY ROSS PHD CHAIR 1.00 X X 0 0 0 STEVEN D PEARSON PRESIDENT 50.00 X 525204 0 46344 SARAH K EMOND TREASURER, SECRETARY, COO 50.00 X 218902 0 34985 PAMELA BRADT CHIEF SCIENTIFIC OFFICER (SINCE MAR 2019) 50.00 X 231714 0 17174 DAVID RIND CHIEF MEDICAL OFFICER 50.00 X 259027 0 44537 DAVID WHITRAP VP OF COMM. & OUTREACH 50.00 X 200283 0 35902 ATHELIA TILSON VP OF DEVELOPMENT 50.00 X 179089 0 18726 RICHARD CHAPMAN DIR OF HEALTH ECONOMICS 50.00 X 209055 0 13081 ANITA CHAN FINANCE DIRECTOR 50.00 X 109095 0 6277 VARUN KUMAR ASSOC DIR OF HEALTH ECON. (UNTIL OCT '19) 50.00 X 107797 0 16747 2040166 0 233773 9 0 1 0 REGENTS OF THE U OF CA 3333 CALIFORNIA STREET STE 315 SAN FRANCISCO CA 94143 RESEARCH 272500 UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE SEATTLE WA 98195 ECONOMIC MODELING 270984 UNIVERSITY OF ILLINOIS 28395 NETWORK PLACE CHICAGO IL 60673 ECONOMIC MODELING 179688 SINGH HEALTHCARE ADVISORS LLC 98 LACONIA STREET LEXINGTON MA 02420 HEALTHCARE ADVISORY 106326 4 9043 10462140 10471183 MEMBERSHIP DUES 900099 355750 355750 CONTRACT SERVICE REVENUE 541700 33967 33967 389717 6969 6969 OTHER INCOME 900099 4253 4253 4253 10872122 389717 0 11222 X 1811887 1397746 200743 213398 1861826 1539847 317178 4801 78477 64906 13369 202 177502 146806 30239 457 236410 191917 26160 18333 49979 11818 38161 19300 19300 1516541 1485088 9140 22313 36452 28472 6329 1651 50188 18121 31988 79 273679 260585 520 12574 262372 249702 8904 3766 168005 166917 1054 34 84608 84608 15114 15114 PROFESSIONAL DEVELOP. 35648 2000 33648 BOARD COSTS 32023 32023 6710011 5563925 868478 277608 127525 115517 1837303 3424065 7443707 10046690 30000 64121 52951 107122 535717 315369 297743 220348 96539 121288 114075 9910517 14188477 270443 435704 545000 90000 265611 215699 1081054 741403 X 1406729 3154748 7422734 10292326 8829463 13447074 9910517 14188477 X 4162111 455500 X X 0 1 X 1 0 X 5481696 286234 14466611 1124458 10471183 31830182 5481696 286234 14466611 1124458 10471183 31830182 27123108 4707074 121 1381 1247 3428 6969 13146 3219 4253 7472 31850800 4540517 0.14780 0.16440 X IN 2014 (THE ORGANIZATION'S FIRST FULL YEAR AS AN INDEPENDENT NON-PROFIT), THE ISSUE OF HIGH DRUG PRICES HIT THE NATIONAL STAGE WITH THE APPROVAL OF NEW CURES FOR HEPATITIS C PRICED AT $1,000 PER PILL. AROUND THE SAME TIME, THE ORGANIZATION WAS FINE-TUNING ITS METHODOLOGY TO DETERMINE FAIR PRICES FOR PRESCRIPTION DURGS. THE PUBLIC'S NEED FOR INDEPENDENT ANALYSES OF FAIR DRUG PRICES CAUSED THE ORGANIZATION TO GROW AT A FAST PACE THAN IT WAS ABLE TO CULTIVATE NEW DONORS TO SUPPORT THE WORK, MEANING IT RELIED ON A FEW SELECT DONORS TO SUPPORT THE SCALING OF THE ORGANIZATION. THE ORGANIZATION HAS BEEN BUILDING ITS INFRASTRUCTURE AROUND THE PUBLIC NEED, NOT AROUND DONORS, WHICH HAS MEANT THE ORGANIZATION FAILED THE 33 1/3% TEST THIS YEAR. LATE IN 2018, THE ORGANIZATION HIRED A FUNDRAISING PROFESSIONAL TO BE SINGULARLY FOCUSED ON INCREASING THE NUMBER OF DONORS FROM THE GENERAL PUBLIC. IN 2019, ICER ADDED A "DONATE" BUTTON TO ITS WEBSITE, AND ICER HAS HAD A 126% INCREASE IN THE NUMBER OF INDIVIDUAL DONORS IN 2019. THE GOVERNANACE BOARD OF THE ORGANIZATION CONTINUES TO BE FOCUSED ON SUPPORTING THE PUBLIC'S INTEREST, AS WE HAVE THE PATIENT, CONSUMER, PROVIDER, AND PAYER PERSPECTIVES REPRESENTED ON THE BOARD, ADVISING ON THE ORGANIZATION'S STRATEGIC PRIORITIES. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: CREDIT CARD REBATES - 2018 AMOUNT: $ 3,219. 2019 AMOUNT: $ 4,253. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 428529 226965 201564 39759 37065 2694 67429 51339 16090 220348 DEFERRED RENT 215699 215699 X 10872122 0 10872122 0 10872122 6710011 0 6710011 0 6710011 PART X, LINE 2: THE ORGANIZATION IS A NONPROFIT CORPORATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES ON TRADE OR BUSINESS PROFITS GENERATED BY ACTIVITIES RELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. THE ORGANIZATION MAY BE SUBJECT TO FEDERAL AND STATE INCOME TAXES FOR PROFITS GENERATED FROM TRADE OR BUSINESS ACTIVITIES UNRELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. AS OF DECEMBER 31, 2019, MANAGEMENT BELIEVES THAT THE ORGANIZATION HAS NOT GENERATED ANY UNRELATED BUSINESS TAXABLE INCOME. THE ORGANIZATION ASSESSES THE RECORDING OF UNCERTAIN TAX POSITIONS BY EVALUATING THE MINIMUM RECOGNITION THRESHOLD AND MEASUREMENT REQUIREMENTS A TAX POSITION MUST MEET BEFORE BEING RECOGNIZED AS A BENEFIT IN THE FINANCIAL STATEMENTS. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ACCRUED ON ANY UNCERTAIN TAX POSITIONS AS A COMPONENT OF INCOME TAX EXPENSE, IF ANY, IN ITS STATEMENTS OF ACTIVITIES. X X X X 0 0 0 0 0 0 0 0 0 STEVEN D PEARSON PRESIDENT 490204 0 35000 0 0 0 25000 0 21344 0 571548 0 0 0 SARAH K EMOND TREASURER, SECRETARY, COO 200402 0 18500 0 0 0 18551 0 16434 0 253887 0 0 0 PAMELA BRADT CHIEF SCIENTIFIC OFFICER (SINCE MAR 228214 0 3500 0 0 0 6572 0 10602 0 248888 0 0 0 DAVID RIND CHIEF MEDICAL OFFICER 240527 0 18500 0 0 0 23281 0 21256 0 303564 0 0 0 DAVID WHITRAP VP OF COMM. & OUTREACH 196783 0 3500 0 0 0 13991 0 21911 0 236185 0 0 0 ATHELIA TILSON VP OF DEVELOPMENT 175589 0 3500 0 0 0 9849 0 8877 0 197815 0 0 0 RICHARD CHAPMAN DIR OF HEALTH ECONOMICS 205555 0 3500 0 0 0 10518 0 2563 0 222136 0 0 0 FORM 990, PART I, LINE 1: ICER IS AN INDEPENDENT, NON-PARTISAN, NON-PROFIT RESEARCH ORGANIZATION THAT OBJECTIVELY EVALUATES THE CLINICAL AND ECONOMIC VALUE OF PRESCRIPTION DRUGS, MEDICAL TESTS, AND OTHER HEALTH CARE INTERVENTIONS. ICER CONDUCTS RIGOROUS ANALYSES OF ALL CLINICAL DATA AND PUBLICLY CONVENES KEY STAKEHOLDERS INCLUDING PATIENTS, DOCTORS, LIFE SCIENCES COMPANIES, AND INSURERS TO TRANSLATE THIS EVIDENCE INTO POLICY DECISIONS THAT LEAD TO A MORE EFFECTIVE, EFFICIENT, AND JUST HEALTH SYSTEM. ICER'S EVIDENCE REPORTS INCLUDE A FULL ANALYSIS OF HOW WELL EACH NEW MEDICINE WORKS, THE ECONOMIC VALUE EACH TREATMENT REPRESENTS, AND OTHER SOCIETAL FACTORS THAT POLICYMAKERS MAY NEED TO CONSIDER. THE REPORTS ESTABLISH HOW EACH DRUG SHOULD BE PRICED TO APPROPRIATELY REFLECT IMPROVED PATIENT OUTCOMES, AND THIS "HEALTH-BENEFIT PRICE BENCHMARK' IS INCREASINGLY GUIDING NEGOTIATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND US PAYER ORGANIZATIONS. ICER'S ULTIMATE GOAL IS TO HELP THE US HEALTH SYSTEM ACHIEVE FAIR DRUG PRICING AND FAIR PATIENT ACCESS, WHILE RETAINING FINANCIAL INCENTIVES FOR FUTURE INNOVATION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS FIRST REVIEWED IN DETAIL BY THE ORGANIZATION'S SENIOR MANAGEMENT TEAM. A FULL COPY OF THE FORM 990 IS THEN PROVIDED TO THE ENTIRE BOARD OF DIRECTORS FOR REVIEW PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CODE OF BUSINESS CONDUCT AND ETHICS, WHICH INCLUDES A CONFLICT OF INTEREST POLICY, IS REVIEWED ON AN ANNUAL BASIS. ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE REQUIRED TO COMPLETE AND SIGN THE CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE OFFICERS OF THE ORGANIZATION IS REVIEWED AND APPROVED BY THE GOVERNING BOARD'S COMPENSATION COMMITTEE ON AN ANNUAL BASIS. IN DOING SO, THE COMPENSATION COMMITTEE REVIEWS COMPENSATION DATA FROM PEER ORGANIZATIONS. COMPENSATION OF ADDITIONAL KEY EMPLOYEES IS REVIEWED AND APPROVED BY THE OFFICERS OF THE ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CODE OF BUSINESS CONDUCT AND ETHICS, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G MARKETING AND COMMUNICATIONS: PROGRAM SERVICE EXPENSES 25,403. MANAGEMENT AND GENERAL EXPENSES 300. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 25,703. OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 59,148. MANAGEMENT AND GENERAL EXPENSES 8,840. FUNDRAISING EXPENSES 22,313. TOTAL EXPENSES 90,301. CONTRACTOR SERVICES: PROGRAM SERVICE EXPENSES 1,400,537. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,400,537. FORM 990, PART XI, LINE 9: CUMULATIVE EFFECT ADJUSTMENT 455,500. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT FOR THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED DURING THE YEAR.